Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response

Cancer Res. 1993 Mar 1;53(5):949-52.

Abstract

A preclinical model was used to determine if transfection of the interleukin 2 (IL-2) gene into human melanoma cells would augment the response of autologous and allogeneic peripheral blood lymphocytes (PBLs) from melanoma patients. IL-2 gene was transfected into three human melanoma cell lines; secretion of IL-2 from stable transfected cells was confirmed by enzyme-linked immunosorbent assay. The PBL response to these melanoma cells was then examined in a mixed-lymphocyte tumor reaction using PBLs from eight melanoma patients. The PBL response to autologous (P < 0.01) or human leukocyte antigen A cross-reactive (P < 0.05) transfected melanoma cells was significantly higher than it was to nontransfected melanoma cells. These data suggest that IL-2 gene transfection may be an important strategic approach to enhancing specific immune responses induced by a polyvalent melanoma cell vaccine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Base Sequence
  • Genetic Therapy
  • HLA-A Antigens / immunology
  • Humans
  • Immunity, Cellular
  • Immunotherapy
  • Interleukin-2 / genetics*
  • Melanoma / immunology*
  • Melanoma / therapy
  • Molecular Sequence Data
  • Transfection*
  • Tumor Cells, Cultured

Substances

  • HLA-A Antigens
  • Interleukin-2